New benzimidazoline-2-oxo-1-carboxylic acid derivatives useful as 5-ht receptor antagonists
申请人:BOEHRINGER INGELHEIM ITALIA S.p.A.
公开号:EP0309423A2
公开(公告)日:1989-03-29
New pharmacologically active benzimidazoline-2-oxo-1-carboxylic acid derivatives which are 5-HT receptor antagonists useful as antiemetic agents and as gastric prokinetic agents of the following formula:
wherein R represents a hydrogen atom, C₁₋₆ alkyl, C₁₋₆ alkenyl or C₁₋₆ alkynil; R₁ and R₂ may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ acyl, carboxyl, C₁₋₆ alkoxycarbonyl, hydroxy, nitro, amino optionally C₁₋₄ alkyl N-mono or di-substituted, C₁₋₆ acylamino, C₁₋₆ alkoxycarbonylamino, carbamoyl optionally C₁₋₄ alkyl N-mono or di-substituted, cyano, C₁₋₆alkylsulphinyl, C₁₋₆ alkylsulphonyl, amino sulphonyl optionally C₁₋₄ alkyl N-mono or di-substituted, C₁₋₄ alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino; Y is oxygen or is N - R₃ in which R₃ is a hydrogen, a C₁₋₆ alkyl or optionally substituted by one or more C₁₋₆ alkoxy benzyl; A is a group selected from:
wherein p is 0, 1; r is 0, 1, 2, 3; R₄ is hydrogen atom or a C₁₋₄ alkyl; R₅ is a hydrogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloalkyl C₁₋₄ alkyl,substituted phenyl C₁₋₄ alkyl or R₅ is a group of formula
wherein R₆ is hydrogen atom, C₁₋₄ alkyl or an amino group and R₇ is hydrogen atom or C₁₋₆ alkyl, tautomers thereof and acid addition salts of the aforesaid compounds.
The processes for the preparation of the compounds of formula (I) as well as pharmaceutical compositions containing them are also described.
具有药理活性的新型
苯并咪唑啉-2-氧代-1-
羧酸衍
生物,该衍
生物为 5-HT 受体拮抗剂,可用作止吐药和促胃动力药,其分子式如下:
其中 R 代表氢原子、C₁₋₆烷基、C₁₋₆烯基或 C₁₋₆炔基;R₁ 和 R₂ 可以同时是或不是氢原子、卤素、三
氟甲基、C₁₋₆ 烷基、C₁₋₆ 烷氧基、C₁₋₆ 烷
硫基、C₁₋₆酰基、羧基、C₁₋₆烷氧基羰基、羟基、硝基、可选的 C₁₋₄烷基 N-单或二取代的
氨基、C₁₋₆酰
氨基、C₁₋₆ 烷氧羰基
氨基、可选 C₁₋₄烷基 N-单或二取代的
氨基甲酰基、
氰基、C₁₋₆ 烷基磺酰基、C₁₋₆ 烷基磺酰基、C₁₋₄ 烷基 N-单或二取代的
氨基磺酰基、C₁₋₄ 烷基 N-单或二取代的
氨基磺酰基、
氨基磺酰基
氨基;Y 是氧或 N - R₃,其中 R₃ 是氢、C₁₋₆ 烷基或任选被一个或多个 C₁₋₆烷氧基取代的苄基; A 是选自以下各项的基团:
其中 p 是 0、1;r 是 0、1、2、3;R₄ 是氢原子或 C₁₋₄ 烷基;R₅ 是氢原子、C₁₋₆ 烷基、C₃₋₈ 环烷基、C₃₋₈ 环烷基 C₁₋₄ 烷基、取代苯基 C₁₋₄ 烷基或 R₅ 是式中的基团。
其中 R₆是氢原子、C₁₋₄烷基或
氨基,R₇是氢原子或 C₁₋₆ 烷基,以及上述化合物的同系物和酸加成盐。
此外,还介绍了制备式 (I) 化合物以及含有这些化合物的药物组合物的工艺。